The Motley Fool

Why GlaxoSmithKline plc Is More Like Unilever plc Than AstraZeneca plc

It used to be that investors in big pharma had a straight choice between GlaxoSmithKline (LSE: GSK) (NYSE:GSK.US) and AstraZeneca (LSE:AZN) (NYSE: AZN.US). They remain the two largest firms in the pharmaceutical sector of the London Stock Exchange, so that thinking still lingers in most investors’ minds.

But GSK’s CEO Andrew Witty has taken his company in a very different direction from Pascal Soriot at Astra. The two companies are no longer comparable, and it distorts the investment case to think of them that way.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

The Unilever of healthcare

Mr Witty has de-emphasised the traditional big pharma strategy, whereby massive up-front investment in R&D aims to discover the next blockbuster drug to fund years of fat profits — most notably through the recent asset-swap with Novartis. He argues that Western governments will eventually baulk at the cost of healthcare for an ageing population, so the next generation of drugs won’t be so profitable. Perhaps the recent patent cliff scare also underlined the risky nature of prescription medicine.

So Mr Witty is emphasising global distribution of branded over-the-counter products and lower-margin vaccines, both of which play into growth in emerging market demand. Global consumer brands, low margins, emerging market growth, that sounds like the Unilever (LSE: ULVR) of healthcare. The two companies’ products even meet tangentially: there are markets where Unilever’s Signal toothpaste is up against GSK’s Aquafresh. The transition of GSK’s Horlicks from a Victorian tonic to India’s leading health drink mirrors the trajectory of Unilever’s Lifebuoy soap.

Biotech with a dividend

When Pascal Soriot took the helm in 2012 he committed AstraZeneca to just the science-heavy, R&D-led drug development that Andrew Witty is turning away from. Facing a steep and treacherous patent cliff, at the time I described Astra as like a biotech company with a dividend attached.

It still is, but three things have played to Mr Soriot’s advantage. To his credit, Astra’s scientists are delivering. Right now it’s creating a stir with immunotherapy, especially as a cancer cure. Secondly, biotech has become a fashionable sector. The thinking is that if you invent the drug, someone will pay for it. Thirdly, Pfizer’s aborted bid boosted Astra’s share price, which has remained elevated on the back of Mr Soriot’s bold confidence in Astra’s standalone earnings potential.

And the winner is…

Which of Mr Witty and Mr Soriot will eventually be proved right? The lesson for investors is that we won’t know until it’s too late. Investors shouldn’t stake too much on guessing what the future holds. Rather they should pick stocks — and plan portfolios — to suit their circumstances.

Personally I like boring but safe GSK. Stocks like GSK and Unilever, which offer bond-like security in their payout whilst locking in emerging market growth, make good cornerstone shares.

I’m wary of Astra’s valuation. Buoyed by lingering bid hopes, Mr Soriot’s big promises, and a biotech sector that could be in a bubble, I perceive bigger downside risk in the share price — but that’s countered by a bigger potential upside.

High yield

Both Astra and GSK offer good dividend yields, if little in the way of near-term dividend growth. That underlines their attraction to many investors, whether you want the income or want to re-invest and enjoy the compound growth in your holding.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Tony Reading owns shares in GlaxoSmithKline and Unilever. The Motley Fool UK has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.